Newsroom | 26744 results

Sorted by: Latest

Hospitals
-

Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025

DOHA, Qatar--(BUSINESS WIRE)--Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025...
-

Auna Announces 4Q25 and FY25 Financial Results

LUXEMBOURG--(BUSINESS WIRE)--Auna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today financial results for the fourth quarter ended December 31, 2025 (“fourth quarter 2025” or “4Q25”) and full-year ended 2025 (“full-year 2025” or “FY25”). Financial results are expressed in Peruvian Soles (“S/” or “PEN”) and are presented in accordance with International Financial Reporting Standards (“IFRS”), unle...
-

Phreesia Named to the 2026 Capterra Shortlist for Appointment Scheduling

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to the 2026 Capterra Shortlist for Appointment Scheduling. The Capterra Shortlist is an independent assessment that uses a proprietary blend of user ratings and popularity signals to identify leading products across software categories. Phreesia was named to four Capterra Shortlists in 2025, including for Patient Engagement. “Recognition from Capterra is especially...
-

Medical Properties Trust Issues Statement on Healthcare Systems of America

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Medical Properties Trust, Inc. (the “Company” or “MPT”) (NYSE: MPT) today issued the following statement regarding litigation involving Healthcare Systems of America (“HSA"). “We are aware that the principals of HSA are currently engaged in litigation in which MPT is not involved. Separately, we have sent certain ordinary course legal notices to HSA intended to protect our legal interests. We do not expect this situation to impact rent collections moving forwa...
-

KARL STORZ Receives FDA Clearance for FIVE S 6.5 Bronchoscope

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in endoscopic and minimally invasive surgical technology, has received FDA clearance for the FIVE S 6.5 sterile single-use bronchoscope. The device offers a valuable new option for critical care physicians, intensivists, RTs, and ICU-based proceduralists seeking airway control solutions for high-risk patients—especially those managing heavy secretions or in urgent situations requiring fast airway clearance. “The FIVE S 6.5 single-...
-

Dallas Nephrology Associates to Receive 2026 Burl Osborne Award from the National Kidney Foundation

DALLAS--(BUSINESS WIRE)--Dallas Nephrology Associates (DNA) is honored to be recognized with the Burl Osborne Award at the National Kidney Foundation’s Bonne Santé 2026 event, taking place on Saturday, March 7, 2026. The award celebrates exceptional philanthropic and corporate leadership in raising awareness about kidney disease and advancing the mission of the National Kidney Foundation (NKF). DNA exemplifies a longstanding commitment to kidney health through patient education, community engag...
-

Ortelius Delivers Open Letter to Surgery Partners Stockholders

NEW YORK--(BUSINESS WIRE)--Ortelius Advisors, L.P. today issued the following open letter to stockholders of Surgery Partners, Inc. (NASDAQ: SGRY). March 10, 2026 Fellow Stockholders, Ortelius Advisors, L.P. (“Ortelius” or “we”) believes that Surgery Partners, Inc. (“Surgery” or the “Company”) has significant upside potential, based on its high-quality assets, favorable industry dynamics, and considerable free cash flow capabilities. However, we are deeply concerned by the Company’s abysmal per...
-

TerSera Therapeutics Announces Closing of Divestiture of Infusion Specialty Therapies Business Unit to ESTEVE

DEERFIELD, Ill. & BARCELONA, Spain--(BUSINESS WIRE)--TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt® (ziconotide intrathecal infusion) and Quzyttir® (cetirizine hydrochloride injection) to ESTEVE. Effective today, under the terms of the transaction, ESTEVE fully owns Prialt® and Quzyttir®. Perella Weinberg Partners acted as the financial advisor to E...
-

Amigo AI Raises $11M Series A to Train Clinical AI Agents Like Doctors

NEW YORK--(BUSINESS WIRE)--Amigo AI, the platform for building and training patient-facing clinical agents, today announced an $11M Series A led by Madrona with participation from Optum Ventures. The company has now raised $17M in total funding, including a seed round co-led by General Catalyst and GSV Ventures. The raise comes amid growing momentum for the application of AI in healthcare, fueled by regulatory shifts toward technology-enabled care delivery (e.g., CMS ACCESS model) and growing p...
-

American Family Care Launches Medically Supervised Weight Management Program at Select Urgent Care Locations

BIRMINGHAM, Ala.--(BUSINESS WIRE)--American Family Care Launches Medically Supervised Weight Management Program at Select Urgent Care Locations...